• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teva Canada completes sale of Mirabel facility to Halo Pharmaceutical

Teva Canada completes sale of Mirabel facility to Halo Pharmaceutical

August 6, 2012
CenterWatch Staff

Teva Canada, a healthcare solutions provider, has completed the sale of its Mirabel manufacturing facility in Montreal to Halo Pharmaceutical, a contract development and manufacturing organization (CDMO) based in Parsippany, N.J.

Until the end of 2012, Halo will continue to manufacture all products currently produced at the Mirabel site, during which time certain of these products will be transferred to Teva's Stouffville facility. In the long term, production of selected Teva Canada products will remain at the site. All existing Teva Canada employees will remain throughout the balance of 2012. In addition, the five year manufacturing agreements also assure the employment of at least 152 employees. Securing supplemental production capacity through the Mirabel site enables Teva Canada to continue to strengthen its drug supply to the Canadian market, ensuring maximum production capacity at other Teva manufacturing sites.

"Successfully concluding this sale and securing the right partner in Halo is a positive outcome for the dedicated employees at Mirabel,” said Barry Fishman, president and CEO, of Teva Canada. β€œThe new contract manufacturing relationship will assist us in maintaining a consistent supply of pharmaceuticals to patients that rely on our products.”

Halo has acquired Teva Canada's state-of-the-art manufacturing facility and related equipment. While the Mirabel plant will continue to support many products for the Canadian market, this addition to Halo's manufacturing network will also allow production to be exported outside of Canada.

"This platform in Mirabel gives us immediate export potential into the European Union, and provides new dosage forms and specialized R&D services for our clients", said Mohd Asif, CFO, Halo Pharmaceutical.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing